Javelin feels the pain as analgesic ketamine fails Phase III trial
This article was originally published in Scrip
Executive Summary
Javelin Pharmaceuticals' Ereska (intranasal ketamine) narrowly missed showing analgesic efficacy in a Phase III trial of subjects experiencing postoperative pain after orthopaedic surgery, show top-line data. The company's share price fell by 27.5%, to $1.48, on AMEX on August 11th on these data.